We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : May 2021
  • Code : CMI4441
  • Pages : 272
  • Formats :
      Excel/PDF
  • Industry : Pharmaceutical

The global urea cycle disorders treatment market includes various therapies such as amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, low protein diet, carglumic acid, etc. for the treatment of the inherited disorder such as urea cycle disorders, which affects various enzymes taking part in the urea cycle pathway in the human system. The urea cycle disorders are classified according to the deficiencies observed in different enzymes of the urea cycle such as OTC – ornithine transcarbamylase, ASD – argininosuccinic acid synthetase (citrullinemia), AG – Arginase, ALD – argininosuccinase acid lyase (argininosuccinic aciduria), CPS – carbamoyl phosphate synthetase, and NAGS – N-acetylglutamate synthetase.

Market Dynamics

Market players are focused on adopting different business strategies such as mergers and acquisitions in order to expand their offerings in the market.

For instance, in February 2017, Mead Johnson Nutrition Company (MJN) announced its merger with Reckitt Benckiser Group plc (RB).  Mead Johnson, now a division of RB, added its globally-recognized brands, including Enfa and Nutramigen, which are used in dietary management of urea cycle disorder, to RB’s consumer health portfolio, thus strengthening its position globally.

Moreover, For Instance, In October 2017, Lucane Pharma SA was acquired by the Eurocept Pharmaceuticals, a company developing, distributing, and marketing of medicinal products in therapeutic areas such as anesthesia, oncology, immunology, and neurology. This acquisition has aided Eurocept Pharmaceuticals to invest in research and development of medicines for rare metabolic diseases such as urea cycle disorders.

Furthermore, Key players focused on inorganic strategies such as distribution agreements in order to strengthen their presence in the market.

For Instance, In 2016, Horizon Pharma plc and Swedish Orphan Biovitrum AB (publ) (Sobi), a biotechnological company in Sweden, announced the distribution agreement for the distribution of Ravicti in European countries including the U.K,. Germany, Italy, France, and Spain.

Key features of the study:

  • This report provides in-depth analysis of the global urea cycle disorders treatment market, provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020–2027)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
  • It profiles leading players in the global urea cycle disorders treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future market expansion and marketing tactics
  • The global urea cycle disorders treatment market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
  • Stakeholders would greatly benefit in decision-making through various strategy matrices used in analyzing the global urea cycle disorders treatment market

Detailed Segmentation:

  • Global Urea Cycle Disorders Treatment Market, By Treatment Type:
    • Amino Acid Supplements
    • Sodium Phenylbutyrate
    • Glycerol Phenylbutyrate
    • Sodium Benzoate
    • Others (Low Protein Diet, Carglumic acid, etc.)
  • Global Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type :
    • OTC – Ornithine Transcarbamylase
    • AS – Argininosuccinate Synthetase (citrullinemia)
    • AG – Arginase
    • AL – Argininosuccinate Lyase
    • CPS1 – Carbamoyl Phosphate Synthase
    • NAGS – N-acetylglutamate Synthase
  • Global Urea Cycle Disorders Treatment Market, By Route of Administration :
    • Oral
    • Injectable
  • Global Urea Cycle Disorders Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Urea Cycle Disorders Treatment Market, By Region:
    • North America
      • By Treatment Type:
        • Amino Acid Supplements
        • Sodium Phenylbutyrate
        • Glycerol Phenylbutyrate
        • Sodium Benzoate
        • Others (Low Protein Diet, Carglumic acid, etc.)
      • By Enzyme Deficiency Type:
        • OTC – Ornithine Transcarbamylase
        • AS – Argininosuccinate Synthetase (citrullinemia)
        • AG – Arginase
        • AL – Argininosuccinate Lyase
        • CPS1 – Carbamoyl Phosphate Synthase
        • NAGS – N-acetylglutamate Synthase
      • By Route of Administration :
        • Oral
        • Injecatble
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Treatment Type:
        • Amino Acid Supplements
        • Sodium Phenylbutyrate
        • Glycerol Phenylbutyrate
        • Sodium Benzoate
        • Others (Low Protein Diet, Carglumic acid, etc.)
      • By Enzyme Deficiency Type:
        • OTC – Ornithine Transcarbamylase
        • AS – Argininosuccinate Synthetase (citrullinemia)
        • AG – Arginase
        • AL – Argininosuccinate Lyase
        • CPS1 – Carbamoyl Phosphate Synthase
        • NAGS – N-acetylglutamate Synthase
      • By Route of Administration :
        • Oral
        • Injecatble
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Treatment Type:
        • Amino Acid Supplements
        • Sodium Phenylbutyrate
        • Glycerol Phenylbutyrate
        • Sodium Benzoate
        • Others (Low Protein Diet, Carglumic acid, etc.)
      • By Enzyme Deficiency Type:
        • OTC – Ornithine Transcarbamylase
        • AS – Argininosuccinate Synthetase (citrullinemia)
        • AG – Arginase
        • AL – Argininosuccinate Lyase
        • CPS1 – Carbamoyl Phosphate Synthase
        • NAGS – N-acetylglutamate Synthase
      • By Route of Administration :
        • Oral
        • Injecatble
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment Type:
        • Amino Acid Supplements
        • Sodium Phenylbutyrate
        • Glycerol Phenylbutyrate
        • Sodium Benzoate
        • Others (Low Protein Diet, Carglumic acid, etc.)
      • By Enzyme Deficiency Type:
        • OTC – Ornithine Transcarbamylase
        • AS – Argininosuccinate Synthetase (citrullinemia)
        • AG – Arginase
        • AL – Argininosuccinate Lyase
        • CPS1 – Carbamoyl Phosphate Synthase
        • NAGS – N-acetylglutamate Synthase
      • By Route of Administration :
        • Oral
        • Injecatble
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment Type:
        • Amino Acid Supplements
        • Sodium Phenylbutyrate
        • Glycerol Phenylbutyrate
        • Sodium Benzoate
        • Others (Low Protein Diet, Carglumic acid, etc.)
      • By Enzyme Deficiency Type:
        • OTC – Ornithine Transcarbamylase
        • AS – Argininosuccinate Synthetase (citrullinemia)
        • AG – Arginase
        • AL – Argininosuccinate Lyase
        • CPS1 – Carbamoyl Phosphate Synthase
        • NAGS – N-acetylglutamate Synthase
      • By Route of Administration :
        • Oral
        • Injecatble
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment Type:
        • Amino Acid Supplements
        • Sodium Phenylbutyrate
        • Glycerol Phenylbutyrate
        • Sodium Benzoate
        • Others (Low Protein Diet, Carglumic acid, etc.)
      • By Enzyme Deficiency Type:
        • OTC – Ornithine Transcarbamylase
        • AS – Argininosuccinate Synthetase (citrullinemia)
        • AG – Arginase
        • AL – Argininosuccinate Lyase
        • CPS1 – Carbamoyl Phosphate Synthase
        • NAGS – N-acetylglutamate Synthase
      • By Route of Administration :
        • Oral
        • Injecatble
      • By Distribution Channel :
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Bausch Health Companies, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Recordati Rare Diseases Inc.
    • Lucane Pharma SA
    • Acer Therapeutics
    • Ultragenyx Pharmaceutical Inc.
    • Aeglea BioTherapeutics
    • Arcturus Therapeutics Holdings Inc.
    • Orpharma Pty Ltd.
    • Selecta Biosciences, Inc.
    • Abbott Laboratories
    • NESTLÉ S.A.
    • DANONE S.A.
    • Mead Johnson & Company, LLC

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Treatment Type
      • Market Snapshot, By Enzyme Deficiency Type
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Opportunities
    • Impact Analysis
    • Key Developments
    • Treatment Approaches
    • Novel Therapies Under Development for the Treatment of UCD
    • Mergers, Collaborations, Acquisitions & Agreements
    • Pipeline Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Product Approvals
    • Market Trends
    • Epidemiology
    • Therapeutics Overview
    • Brand Analysis
    • Reimbursement Scenario
    • Prescription Overview
  4. Global Urea Cycle Disorders Treatment Market, Impact of COVID-19 Pandemic
    • COVID-19 Impact on Overall Healthcare Sector
    • COVID-19 Epidemiology
    • Impact of COVID-19 Impact on Supply Chain
    • Covid-19 Impact on Clinical Trials and Drug Development
  5. Global Urea Cycle Disorders Treatment Market, By Treatment Type, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Amino Acid Supplements
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Sodium Phenylbutyrate
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Glycerol Phenylbutyrate
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Sodium Benzoate
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Others (Low Protein Diet, Carglumic acid, etc.)
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Global Urea Cycle Disorders Treatment  Market, By Enzyme Deficiency Type, 2016-2027 (US$ Mn)
    • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017–2027
    • Segment Trends
        • OTC – Ornithine Transcarbamylase
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • AS – Argininosuccinate Synthetase (citrullinemia)
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • AG – Arginase
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • AL – Argininosuccinate Lyase
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • CPS1 – Carbamoyl Phosphate Synthase
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • NAGS – N-acetylglutamate Synthase
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  7. Global Urea Cycle Disorders Treatment Market, By Route of Administration, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Oral
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Injectable
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  8. Global Urea Cycle Disorders Treatment Market, By Distribution Channel, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Hospital Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Retail Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Online Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  9. Global Urea Cycle Disorders Treatment Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Treatment Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Enzyme Deficiency Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  10. Competitive Landscape
    • Company Profiles
      • Bausch Health Companies, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Recordati Rare Diseases Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lucane Pharma SA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Acer Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ultragenyx Pharmaceutical Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aeglea BioTherapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Arcturus Therapeutics Holdings Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Orpharma Pty Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Selecta Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • NESTLÉ S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • DANONE S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mead Johnson & Company, LLC
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

*Browse 72 market data tables and 48 figures on " Urea Cycle Disorders Treatment Market – Global forecast to 2027”.

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.